tbuckley/cabot-search huggingface dataset:
An Unsuspected Diagnosis Initially Detected With Cholescintigraphy
Authors: KENNETH H. PRYOR, EUGENE D. SILVERMAN, RICHARD S. BAKALAR
Journal: Clinical Nuclear Medicine (1995)

A 40-year-old woman had severe right side abdominal pain that she had experienced intermittently during the previous 10 years. Delayed Cholescintigraphy showed radiotracer in the small bowel which occupied only the right side of the abdomen. Intestinal nonrotation was confirmed by a barium small bowel exam.
SP0037 Treatment in RA and SPA During Pregnancy: Present and Future
Authors: M. Ostensen
Journal: Annals of the Rheumatic Diseases (2015)

New effective therapies during the last 15 years have improved outcome and quality of life in patients with rheumatoid arthritis (RA) and spondylarthropathies (SpA). More female patients consider pregnancy. However, adjustements of therapy before and during pregnancy are required. Classical disease modifying drugs (cDMARDs), prednisone, and non-steroidal anti-inflammatory drugs (NSAIDs) remain valid options for treatment of pregnant patients because their safety profile in regard to the fetus is known. Among cDMARDs antimalarials, sulfasalazine, azathioprine, and cyclosporine are compatible with use throughout pregnancy. Methotrexate and cyclophosphamide are teratogenic and must be discontinued before a planned pregnancy. In spite of no indication for teratogenicity in humans, child safety has still not been established for leflunomide, so a washout procedure should be completed before conception. Prolonged and high doses (&gt;7.5 mg/day) of prednisone carry risk for side effects in mother and fetus and should be avoided during pregnancy. In contrast to cDMARDs, child safety is a concern for new biologics with no or little pregnancy experience, and for combination therapies which include methotrexate or leflunomide. TNFα – inhibitors (TNFi) are the best studied biologics. Related to their differences in structure transplacental passage varies with high amounts of transfer in late pregnancy for monoclonal TNFi that posess a Fc part of IgG1. TNFi with either small affinity to the fetal Fc receptor or with no Fc part show low transplacental passage to the child. TNFi can be given before conception and during the first and early 2nd trimester of pregnancy. When possible Fc containing TNFi should be avoided in the third trimester. Studies that investigate child health, particularly infection rate in the first year after antenatal exposure to TNFi are in progress and will provide answers how best to use TNFi in pregnant patients. For most other biologicals data on human pregnancy exposure are sparse. Decisions for treatment during pregnancy in regard to biologics targeting B-cells, T cell activation or cytokines like IL-6, IL-23, IL-17 or IL-1β must be based on the severity of maternal disease and have to be reserved for cases where no other safe options are available. Publications on fetal side effects or long term outcomes of in utero exposed children for rituximab, abatacept, tocilizumab, ustekinumab and anakinra are few and cannot guarantee safety for the child. They are therefore best avoided during pregnancy. In order to prevent unintended pregnancy exposure to insufficiently studied biologicals, often in combination with MTX, family planning should be discussed and counseling given on contraception to patients of fertile age. <h3>References</h3> Østensen, M, Förger, F. Management of RA medications in pregnant patients. Nat. Rev. Rheumatol 2009; 5: 382–390. <h3>Disclosure of Interest</h3> None declared
The end of the pandemic – what will be the pattern of influenza in the 2010-11 European winter and beyond?
Authors: A Nicoll, M Sprenger
Journal: Eurosurveillance (2010)

Preview this article: The end of the pandemic – what will be the pattern of influenza in the 2010-11 European winter and beyond?, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/15/32/art19637-en-1.gif
False-Positive Finding on 18F FDG PET/CT
Authors: Mohammed Shah Alam, Wei Guan, Wen-lan Zhou, Quan-shi Wang, Hu-bing Wu
Journal: Clinical Nuclear Medicine (2016)

Xanthogranulomatous inflammation in the spinal epidural space is extremely rare. We report a case of a 62-year-old man with a xanthogranulomatous inflammation in the spinal epidural space mistaken for lymphoma because of its avid F FDG uptake on PET/CT. This case emphasizes the need for caution when evaluating a spinal epidural mass using F FDG PET/CT as xanthogranulomatous inflammation can induce a false-positive reading on F-FDG PET/CT.
PTU-063 Compliance in inflammatory bowel disease (IBD) patients: how big is the problem, who do they tell and what can be done?
Authors: P Kaimakliotis, AA Soubieres, A Poullis
Journal: Gut (2015)

<h3>Introduction</h3> Compliance with medication reduces the risk of flares and longer term complications in IBD. Drug non-compliance has been shown to be associated with a 12.5% increase in medical costs.<sup>1</sup> <h3>Aims and objectives</h3> To assess and gain insight into the medication adherence of IBD patients and to explore possible solutions. <h3>Method</h3> Data was collected using a self-reporting paper-based questionnaire. Patients were contacted directly using convenience sampling in the IBD clinics. Patients were split broadly into two groups: immunomodulator (IM) and 5-aminosalicylic acid (5-ASA) groups for analysis. The questionnaire included questions about drug compliance, reasons for missing doses, possible solutions to non-compliance, and if patients reported non-compliance to the professionals responsible for their care. <h3>Results</h3> 147 patients completed the questionnaire. 77 participants were male (52.4%), 67 had Crohn’s, 69 UC, 8 indeterminate colitis, 3 were unsure. 105 patients were included in the 5-ASA group and 67 in the IM group (there were 25 patients who were taking both IM and 5-ASA drugs). Patients from both groups were more likely to take their medication when symptomatic: Always take: 61% in 5-ASA group, 38% in IM group; Very often take 7% in 5-ASA group, 4% in IM. Compliance dropped when asymptomatic: always take: 48% in 5-ASA group, 38% in IM group; very often take 10% in 5-ASA group, 7% in IM group. Only 5% inform their medical team of compliance problems. Suggested solutions to aid compliance (% of participants agreeing): Once a day dosing (20%), more contact with IBD team (19%), text reminders (14%), reduced pill burden (12%), more drug information (12%), phone calls (4%), e-mail reminders (3%). <h3>Conclusion</h3> Self reported drug compliance in IBD is a significant problem. Compliance appears to be poorer for IM drugs than 5-ASA’s. The attending medical team is often not informed of possible compliance problems. Solutions include medication review to ease timing and pill burden, education with more contact and information on therapies and communication via text, phone call and e-mail reminders. <h3>Disclosure of interest</h3> None Declared. <h3>Reference</h3> Zelante A, De Giorgi A, Borgoni R, Trevisani L, Gallerani M. Adherence to medical treatment in inflammatory bowel disease. Minerva Gastroenterol Dietol. 2014;60(4):269–74
&lt;italic&gt;Trans&lt;/italic&gt; Fatty Acids in Tumor Development
Authors: J. Edward Hunter, Ph.D.
Journal: JNCI Journal of the National Cancer Institute (1982)

Trans Fatty Acids in Tumor Development Get access J. Edward Hunter, Ph.D. J. Edward Hunter, Ph.D. Biological Subcommittee Institute of Shortening and Edible Oils, Inc., 1750 New York Avenue, N. W. Washington, D. C. 20006 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 69, Issue 2, August 1982, Pages 319–320, https://doi.org/10.1093/jnci/69.2.319 Published: 01 August 1982
ABDOMINAL SURGERY WITHOUT GASTROINTESTINAL SUCTION
Authors: I F STEIN, H S LANS
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Communication of the cancer diagnosis to pediatric patients: impact on long-term adjustment
Authors: L A Slavin, J E O'Malley, G P Koocher, D J Foster
Journal: American Journal of Psychiatry (1982)

A total of 1 16 long-term survivors of childhood malignancies were interviewed by a psychologist and a psychiatrist, who independently assigned adjustment ratings to each patient. Semistructured interviews determined how soon after the initial diagnosis survivors learned they had cancer and whether they had been told by a parent or physician or had learned of the diagnosis in some other way. Good psychosocial adjustment was associated with patients’ early knowledge of the diagnosis. A high percentage of the survivors, their parents, and siblings felt that the cancer diagnosis should be shared with the child early on.
OC-079 Previous exposure to hepatitis b infection and liver outcomes in a population with hepatitis c
Authors: R Swann, H Wang, E Thomas, H Innes, C Schnier, S Hutchinson, PR Mills, J Dillon
Journal: Gut (2015)

<h3>Introduction</h3> Coinfection with HCV and HBV is associated with adverse liver outcomes.<sup>1</sup>While most patients who are acutely infected with HBV in adulthood will clear the virus, up to 80% continue to have evidence of persistent HBV DNA in their liver.<sup>2</sup>The clinical impact of previous HBV infection on liver outcomes in HCV infection is unknown. In the UK, HBV vaccination is only targeted at high risk groups and uptake of this is incomplete. Therefore assessing any additional risk of liver disease posed by previous HBV infection is of importance to public health policy. We aimed to determine any association of previous HBV infection with adverse liver outcomes in a large Scottish cohort of HCV infected patients, using anti-HBV core antibody (Anti-HBc) positivity as a marker of previous exposure. <h3>Method</h3> The Scottish HCV Clinical Database containing clinical data for all patients attending HCV clinics in participating health boards was linked to the HBV virology database and Information Services Division, Scotland data on mortality and hospital admission data. Duplicate patient records, those with no recorded positive HCV RNA and those with incomplete HBV status were excluded from the analysis. Univariate and multivariate cox regressional models and Accelerated Failure Time models were constructed for time to clinical diagnosis of cirrhosis and hepatocellular carcinoma. Models were fitted using both date of birth and date of diagnosis with last follow up or death used as censor date. <h3>Results</h3> 9,573 patient records were included in the analysis (197 HBsAg positive, 1723 Anti-HBc positive, HBsAg negative, 7653 Anti-HBc negative). Previous HBV infection (Anti-HBc positive, HBsAg negative) was significantly associated with development of cirrhosis (HR 1.46, 1.29–1.65) and development of HCC (HR 1.67<i>, </i>1.17–2.37) on multivariate analysis. These associations remained significant in all models fitted. Other factors associated with poorer outcome were alcohol excess, older age, male sex and genotype 3 HCV. Achieving SVR and IVDU were associated with lower risk of cirrhosis and HCC. <h3>Conclusion</h3> This is the largest study to date to show an association between previous HBV infection and adverse liver outcomes in HCV infection. Our data complements a growing body of evidence which suggests HBV infection may have adverse effects on liver health despite apparent clearance. This has important implications for the UK HBV vaccination policy and requires further investigation. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Zarski JP, Bohn B, Bastie A, <i>et al</i>. J Hepatol. 1998;28:27–33 Sagnelli E, Imparato M, Coppola N, <i>et al</i>. J Med Virol. 2008;80:1547–1553
A new approach to collecting biobank and bioinformatics data at Kyoto University Cancer Center
Authors: Manabu Muto, Yu Uneno, Yoshitaka Nishikawa, Yukiko Mori, Masashi Kanai, Shigemi Mastumoto, Genta Kato, Tomohiro Kuroda, Satoshi Morita, Yasushi Okuno
Journal: Annals of Oncology (2015)
Hepatosplenic Candidiasis
Authors: Nermin Halkic, Riadh Ksontini
Journal: New England Journal of Medicine (2007)

A 19-year-old woman underwent five cycles of chemotherapy for acute myelomonocytic leukemia that had been diagnosed 7 months earlier.During the last cycle of chemotherapy, neutropenia developed, lasting 22 days, during which she had fever that was treated with empirical antibacterial therapy.When the neutrophil count increased, the fever persisted.Her evaluation was notable for a peak temperature of 39.5°C and an increase in the serum alkaline phosphatase level to 335 U per liter.An abdominal computed tomographic (CT) scan showed multiple hypodense lesions in the liver and spleen - findings that were consistent with hepatosplenic microabscesses (Panel A, arrows).Since the diagnostic evaluations were unrevealing, diagnostic laparoscopy was performed to obtain biopsy specimens of the hepatic lesions (Panel B, arrows).The causative agent was identified on polymerase-chain-reaction assay as Candida albicans.She was treated with fluconazole, and after 1.5 months of therapy, her body temperature was normal.Her serum alkaline phosphatase level had decreased to 185 U per liter, and a follow-up abdominal CT scan showed a decrease in the size and number of lesions in the liver and spleen.Two months later, she underwent successful hematopoietic stem-cell transplantation.Fifteen months afterward, the acute myelomonocytic leukemia recurred, resulting in death from complications of the disease.The diagnosis of hepatosplenic candidiasis is often difficult to make because of a nonspecific clinical presentation.In immunocompromised patients, an unexplained fever that is unresponsive to antibiotic agents should raise the possibility of an invasive fungal infection.
Fixed Erythema on the Abdomen in a Hematologic Patient
Authors: Isabella Fried, Michael Buslau, Werner Kempf
Journal: JAMA Dermatology (2016)

A man in his 60s presented with a 2-month history of painful, occasionally pruritic, fixed erythema on the abdomen and a splenic marginal zone lymphoma with bone marrow infiltration. What is your diagnosis?
A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis
Authors: F.M. Ali, A.C. Cueva, J. Vyas, A.A. Atwan, M.S. Salek, A.Y. Finlay, V. Piguet
Journal: British Journal of Dermatology (2016)

Planners of interventional studies in psoriasis face the dilemma of selecting suitable quality-of-life (QoL) measures. Systematic reviews have the potential of identifying psychometrically sound measures in a given therapeutic area, while guiding the development of practice guidelines. The aim of this systematic review was to generate evidence of the use of QoL instruments in randomized controlled trials (RCTs) for interventions in psoriasis. The methodology followed the PRISMA guidelines. Six databases were searched with 388 search terms. Abstracts of articles were reviewed independently by two assessors, and a third adjudicator resolved any opinion differences. Risk of bias was assessed using the Jadad scale. Of 3646 screened publications, 99 articles (100 trials) met the eligibility criteria for inclusion, describing research on 33 215 patients. Thirty-three trials tested topical therapy, 18 systemic, 39 biologics, nine phototherapy and 10 other interventions. The Dermatology Life Quality Index (DLQI) was the most commonly used QoL instrument (83 studies, 83%), followed by the 36-Item Short Form Survey (SF-36) (31, 31%), EuroQoL-5D (EQ-5D) (15, 15%), Psoriasis Disability Index (14, 14%) and Skindex (five, 5%). There was widespread inconsistency in the way that QoL data were reported. Of the 100 trials identified, 37 reported minimal clinically important difference (MCID): 32 for DLQI, 10 for SF-36 and six for EQ-5D. QoL measurement is increasingly being reported in RCTs of psoriasis. Formal guidelines are needed for assessment and publishing of QoL data. Researchers should consider whether MCID information is available, and development of MCID data should be encouraged.
Electrolyte and Fluid Disturbances in Congestive Heart Failure
Authors: Charles K. Friedberg
Journal: New England Journal of Medicine (1951)

Effect of Sodium-Chloride Ingestion in Heart FailureStudies to determine whether cardiac edema followed a primary retention of sodium and water or was first preceded by an elevation in venous pressure were made by administering 10 gm. of sodium chloride daily to patients previously treated for heart failure. Such studies were reported to show the recurrence of cardiac edema, as denoted by weight gain, before the venous pressure became elevated.97 Later studies were ineffective in determining such a sequence, both gain in weight and elevation of venous pressure occurring virtually at the same time.98 , 99 In interpreting such studies it is . . .
Psychiatric complications of disulfiram treatment
Authors: L Branchey, W Davis, K K Lee, R K Fuller
Journal: American Journal of Psychiatry (1987)

The authors studied psychiatric complications of disulfiram use in 605 alcoholic patients. The subjects were assigned to one of three treatment groups: a 250-mg disulfiram group (N = 202), a 1-mg disulfiram group (N = 204) to control for the fear of the alcohol-disulfiram reaction, and a no-disulfiram group (N = 199) to control for the effect of psychotherapy. No significant differences in the incidence of psychiatric complications were found among the three groups. The authors conclude that if psychiatric complications follow disulfiram use, the incidence must be very low with the doses of disulfiram used presently and in the absence of predisposing factors.
AB0572 Antiphospholipid Antibodies Profile and Thrombosis Recurrence
Authors: G. Medina, O.I. Florez, G. Montiel Manzano, E. Reyes Maldonado, P. Cruz Domínguez, L. Olguín Ortega, M.A. Saavedra Salinas, L.J. Jara
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The serological test included in the classification for antiphospholipid syndrome are: IgG, IgM antibodies to cardiolipin (aCL), β2-glycoprotein (anti-β2GPI) and the lupus anticoagulant (LA). Among these antiphospholipid (aPL) antibodies, LA is considered the strongest risk factor for thromboembolic events and triple positivity of antiphospholipid antibodies (aPL)(Lupus anticoagulant /LA), aCL and antiβ2GPI) are at the highest risk for thrombosis recurrence and obstetric complications, even while on anticoagulant therapy. <h3>Objectives</h3> To analyze the role of 4 antiphospholipid antibodies in thrombotic recurrence of patients with antiphospholipid syndrome (APS). <h3>Methods</h3> In a cross-sectional study, we included patients with established diagnosis of APS from 1996 to 2014. The clinical files were reviewed and we obtained demographic, clinical, and treatment data. Blood samples were taken to determine titers of aPL: aCL, anti anexin 5 (anti A5), antiβ2GPI IgG and IgM by ELISA method, and LA in plasma by the coagulation method. <h3>Results</h3> 70 APS patients were studied, 56 females and 14 males, 67 with primary APS and 3 with associated APS. The mean age was 44±12.9 years (range 18-77 years) mean disease evolution 10.8±5.8 years, thrombosis recurrence was observed in 38 patients (53.5%) and 33 patients without thrombosis recurrence (46.5%); 67 patients treated with traditional oral anticoagulants, 47 (66%) had venous thrombosis,12 (17%) had arterial thrombosis and10 (14%) had venous and arterial thrombosis. Prevalence of aPL was: 35 for IgG aCL (49.3%), 21 for IgM aCL (29.6%), 36 for IgG antiβ2GPI (50.7%), 12 for IgM antiβ2GPI (15.5%), 3 for IgG antiA5 (4.2%), 5 for IgM anti A5 (7%) and 34 for LA (46.5%), 25 patients had triple positivity for aPL (35.2%.) and 16 patients had at time of study a negative aPL profile, even though some of them had thrombosis recurrence and aPL positive in the past. Regression analysis for all aPL and thrombosis recurrence showed an OR of 7.3 CI 95%=1.19-45.1) for LA (p=0.03) <h3>Conclusions</h3> Our study confirm that LA seems to be the most important aPL, which presence confers a major risk of thrombosis recurrence. Careful follow-up of patients with persistence of LA should be recommended to avoid thrombosis recurrence. A negative "traditional" aPL profile seems to be not an indication for stop anticoagulation. <h3>References</h3> Forastiero R. Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. Lupus. 2014 Oct;23(12):1252-4. Hernández-Molina G, Espericueta-Arriola G, Cabral AR.The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin Exp Rheumatol. 2013 May-Jun;31(3):382-8. <h3>Disclosure of Interest</h3> None declared
BASAL-CELL NEVUS SYNDROME
Authors: V Semrádová, R Caha
Journal: JAMA (1964)

The authors describe pathological changes, incl. X-ray changes and histological documentation, in two patients with the syndrome of naevoid basiliomas. In the treatment cryosurgery proved useful. In the discussion the authors summarize literary data on the frequency of basiliomas in different organs and systems of ectodermal and mesodermal origin and on the incidence of malignant tumours. They emphasize interdisciplinary cooperation, early establishment of the diagnosis and dispensarization of the patients.
Endosomal acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate endosomal escape
Authors: Ji-Sun Kim, Dong-Ki Choi, Ju-Yeon Shin, Seung-Min Shin, Seong-Wook Park, Hyun-Soo Cho, Yong-Sung Kim
Journal: Journal of Controlled Release (2016)
What determines actual chemotherapy dose intensity?
Authors: M H Cohen
Journal: Journal of Clinical Oncology (1990)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1990.8.11.1926 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2230882 What determines actual chemotherapy dose intensity? M H CohenxM H CohenSearch for articles by this author https://doi.org/10.1200/JCO.1990.8.11.1926 PDF "What determines actual chemotherapy dose intensity?." Journal of Clinical Oncology, 8(11), p. 1926© 1990 by American Society of Clinical Oncology